Trial · NCT02097225
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose of Dabrafenib | Treatment (Dabrafenib, Trametinib, Onalespib) | 150 | mg | ||
| Maximum Tolerated Dose of Trametinib | Treatment (Dabrafenib, Trametinib, Onalespib) | 2 | mg | ||
| Maximum Tolerated Dose of Onalespib | Treatment (Dabrafenib, Trametinib, Onalespib) | 260 | mg/m2 | ||
| Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | Grade 3 toxicity | 0 | dose limiting toxicities | |
| Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | Grade 3 toxicity | 0 | dose limiting toxicities | |
| Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | Grade 3 toxicity | 5 | dose limiting toxicities | |
| Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | Grade 3 toxicity | 1 | dose limiting toxicities | |
| Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | Grade 4 toxicity | 0 | dose limiting toxicities | |
| Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | Grade 4 toxicity | 0 | dose limiting toxicities | |
| Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | Grade 4 toxicity | 0 | dose limiting toxicities | |
| Number of Dose Limiting Toxicities While Determining Maximum Tolerated Dose | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | Grade 4 toxicity | 0 | dose limiting toxicities | |
| Objective Response Rate | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | Complete response (CR) | 0 | Participants | |
| Objective Response Rate | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | Complete response (CR) | 0 | Participants | |
| Objective Response Rate | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | Complete response (CR) | 0 | Participants | |
| Objective Response Rate | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | Complete response (CR) | 0 | Participants | |
| Objective Response Rate | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | Partial response (PR) | 0 | Participants | |
| Objective Response Rate | Dose Level 2: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 180 mg/m2 | Partial response (PR) | 0 | Participants | |
| Objective Response Rate | Dose Level 3: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 220 mg/m2 | Partial response (PR) | 2 | Participants | |
| Objective Response Rate | Dose Level 4: Dabrafenib = 150 mg, Trametinib = 2 mg, Onalespib = 260 mg/m2 | Partial response (PR) | 0 | Participants | |
| Progression-free Survival | Dose Level 1: Dabrafenib = 150 mg, Trametinib = 1 mg, Onalespib = 180 mg/m2 | 1.6 | 90% Confidence Interval 0.9 to 1.7 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02097225/results